RALLYBIO CORPORATION (RLYB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 3.57M USD | Liabilities, Current |
| Cash and equivalents | 92.85M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.57M | $92.85M | $0.00 | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.14M | $41.30M | $5.50M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $4.22M | $31.37M | $23.36M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $4.52M | $32.12M | $27.20M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $5.04M | $9.45M | $36.30M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $3.91M | $14.78M | $39.72M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $6.24M | $13.90M | $51.61M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $8.19M | $25.32M | $49.82M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $12.16M | $16.67M | $71.94M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $10.09M | $19.30M | $74.87M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $9.26M | $24.49M | $85.44M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $9.40M | $19.16M | $102.23M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $8.05M | $32.56M | $105.28M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $6.80M | $39.52M | $110.87M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $10.74M | $56.96M | $112.04M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $11.29M | $51.71M | $80.71M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $7.28M | $60.75M | $86.61M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.80M | $81.42M | $79.98M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.55M | $175.33M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $7.34M | $186.98M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $7.41M | $112.73M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $5.84M | $140.23M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |